Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Statistics
Share Statistics
Wave Life Sciences has 153.49M shares outstanding. The number of shares has increased by 25.32% in one year.
| Shares Outstanding | 153.49M |
| Shares Change (YoY) | 25.32% |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | 97.79% |
| Shares Floating | 122.54M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 9.94M, so 6.52% of the outstanding shares have been sold short.
| Short Interest | 9.94M |
| Short % of Shares Out | 6.52% |
| Short % of Float | 11.22% |
| Short Ratio (days to cover) | 7.56 |
Valuation Ratios
The PE ratio is -17.63 and the forward PE ratio is -6.04. Wave Life Sciences's PEG ratio is -0.6.
| PE Ratio | -17.63 |
| Forward PE | -6.04 |
| PS Ratio | 15.79 |
| Forward PS | 2 |
| PB Ratio | 8.16 |
| P/FCF Ratio | -11.33 |
| PEG Ratio | -0.6 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Wave Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.89 |
| Quick Ratio | 2.89 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.23 |
| Debt / FCF | -0.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $377.36K |
| Profits Per Employee | $-338.01K |
| Employee Count | 287 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 21.56% in the last 52 weeks. The beta is -0.94, so Wave Life Sciences's price volatility has been lower than the market average.
| Beta | -0.94 |
| 52-Week Price Change | 21.56% |
| 50-Day Moving Average | 9.23 |
| 200-Day Moving Average | 9.84 |
| Relative Strength Index (RSI) | 33.77 |
| Average Volume (20 Days) | 1.18M |
Income Statement
In the last 12 months, Wave Life Sciences had revenue of 108.3M and earned -97.01M in profits. Earnings per share was -0.7.
| Revenue | 108.3M |
| Gross Profit | 108.3M |
| Operating Income | -110.4M |
| Net Income | -97.01M |
| EBITDA | -110.4M |
| EBIT | -110.4M |
| Earnings Per Share (EPS) | -0.7 |
Balance Sheet
The company has 302.08M in cash and 25.4M in debt, giving a net cash position of 276.67M.
| Cash & Cash Equivalents | 302.08M |
| Total Debt | 25.4M |
| Net Cash | 276.67M |
| Retained Earnings | -1.12B |
| Total Assets | 352.21M |
| Working Capital | 209.44M |
Cash Flow
In the last 12 months, operating cash flow was -151.03M and capital expenditures 0, giving a free cash flow of -151.03M.
| Operating Cash Flow | -151.03M |
| Capital Expenditures | 0 |
| Free Cash Flow | -151.03M |
| FCF Per Share | -1.09 |
Margins
Gross margin is 100%, with operating and profit margins of -101.94% and -89.57%.
| Gross Margin | 100% |
| Operating Margin | -101.94% |
| Pretax Margin | -89.57% |
| Profit Margin | -89.57% |
| EBITDA Margin | -101.94% |
| EBIT Margin | -101.94% |
| FCF Margin | -139.45% |
Dividends & Yields
WVE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for WVE is $22, which is 271.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 271.6% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | -0.6 |
| Piotroski F-Score | 2 |